San Francisco, California, Nov 02, 2018: A report by TMR Research, titled, “Stem Cell Assay Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025,” begins by providing a basic definition of the process. It states that stem cell assay refers to the process of gauging the potency of antineoplastic drugs. It primarily comprises of quantitative and qualitative testing or analysis of the tumors or tissues that have been affected. It helps to gauge the impurity, toxicity, and other aspects of the market.
Get Sample Copy of this Report @
With the surging cases of successful stem cell therapy treatment, the report predicts the global stem cell assay market to rise further in the near term. Numerous health conditions ranging from stroke, diabetes, retinal disease, cancer, Parkinson’s and neurological diseases can be treated accurately with stem cell assay. Apart from that, continued thrust on research and development in the area is also boding well for the market. For example, a group of scientists have tried to manipulate stem cells to cure kidney, eye, and heart injuries.
A noticeable trend in the global stem cell assay market is the creation of more cutting-edge stem cell therapies. With respect to geography, the report finds that the global stem cell assay market is being mainly led by North America and Europe. This is because of the rising cases of chronic ailments in the two regions resulting mainly from the unhealthy eating habits and lifestyle of people. Apart from that, a well-developed healthcare setup and state-of-the-art research and development centers too are having a positive impact on the stem cell assay market in the region. Going forward however, the market growth would be maximum in Asia Pacific owing to its large population and strengthening healthcare infrastructure.
Read Comprehensive Overview of Report @
Key players in the global stem cell assay market that have been profiled in the report include Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., GE Healthcare, Hemogenix Inc., and Promega Corporation.